
From cigarettes to gambling, users report that GLP-1 agonists seem to quiet the craving voice that drives addictive behaviors.
Based on 534+ community reports, GLP-1 agonists appear to reduce cravings for various addictive substances and behaviors beyond food and alcohol. Users report easier smoking cessation, reduced gambling urges, and diminished cravings for other substances. This supports the theory that GLP-1s modulate fundamental reward pathways rather than appetite-specific mechanisms.
“Trying to quit smoking for 15 years. On semaglutide for weight loss and the nicotine cravings just... lessened.”
“I was a pack-a-day smoker. Month 2 on Ozempic and I just... stopped. Didn't even try to quit.”
“The gambling urge that's plagued me for years feels so much weaker. Wasn't expecting that from a weight loss drug.”
The peptides most frequently mentioned in relation to this topic
Common questions about glp-1 agonists and addiction craving reduction
No, GLP-1 agonists are not approved for any addiction. Clinical trials are investigating their potential for alcohol use disorder, but other addictions are less studied.
Some users report easier smoking cessation, but this isn't a guaranteed or approved effect. GLP-1s may help by reducing cravings, but quitting still requires effort and possibly other support.
Most reports involve Semaglutide and Tirzepatide, the most commonly used GLP-1s for weight loss. The effect likely applies to the class but individual responses vary.
Browse our complete database of peptides and community experiences
Research Disclaimer: This content compiles community-reported experiences and published research for informational purposes only. Peptides discussed are research chemicals, not FDA-approved medications. This is not medical advice. Always consult a qualified healthcare provider before considering any peptide use.